WO2009041567A1 - メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体 - Google Patents
メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体 Download PDFInfo
- Publication number
- WO2009041567A1 WO2009041567A1 PCT/JP2008/067406 JP2008067406W WO2009041567A1 WO 2009041567 A1 WO2009041567 A1 WO 2009041567A1 JP 2008067406 W JP2008067406 W JP 2008067406W WO 2009041567 A1 WO2009041567 A1 WO 2009041567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- melanin
- hydrogen atom
- hormone receptor
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
【課題】 中枢性疾患、循環器系疾患、代謝性疾患用の医薬品として有用な、メラニン凝集ホルモン受容体の拮抗剤を提供することを目的とする。 【解決手段】 式(I) [式中、R1a及びR1bは、独立して、水素原子又はC1-6アルキル基を表し、R2a、R2b、R3a及びR3bは、独立して、水素原子、C1-6アルキル基等を表し、Yは、H又は-OHを表し、Zは、-OR8等を表し、R8は、水素原子、置換基を有していてもよいC1-6アルキル基等を表し、R9a、R9bは、水素原子、C1-6アルキル基等を表し、Ar1は、芳香族炭素環基又は芳香族複素環基を表し、Ar2は、芳香族炭素環から2個の水素原子を除いて形成される基等を表し、A環基は、不飽和複素環基を表す]で表される化合物を有効成分とする。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/676,938 US20100324049A1 (en) | 2007-09-27 | 2008-09-26 | Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007251356 | 2007-09-27 | ||
JP2007-251356 | 2007-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009041567A1 true WO2009041567A1 (ja) | 2009-04-02 |
Family
ID=40511447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/067406 WO2009041567A1 (ja) | 2007-09-27 | 2008-09-26 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20100324049A1 (ja) |
WO (1) | WO2009041567A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010147234A1 (en) * | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
WO2011162368A1 (ja) * | 2010-06-25 | 2011-12-29 | 興和株式会社 | 新規な縮合ピリジン又は縮合ピリミジン誘導体及びこれを含有する医薬 |
JP2012526737A (ja) * | 2009-05-12 | 2012-11-01 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
US9708315B2 (en) | 2013-09-06 | 2017-07-18 | Janssen Pharmaceutica Nv | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors |
US10106542B2 (en) | 2013-06-04 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11071729B2 (en) | 2007-09-14 | 2021-07-27 | Addex Pharmaceuticals S.A. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones |
JP2021528488A (ja) * | 2018-06-07 | 2021-10-21 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
US11369606B2 (en) | 2014-01-21 | 2022-06-28 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009154132A1 (ja) * | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069798A1 (ja) * | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
JP2004536104A (ja) * | 2001-07-05 | 2004-12-02 | シナプティック・ファーマスーティカル・コーポレーション | Mch選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体 |
WO2006041635A2 (en) * | 2004-10-08 | 2006-04-20 | H. Lundbeck A/S | Arylthiobenzylpiperidine derivatives |
WO2006041636A2 (en) * | 2004-10-08 | 2006-04-20 | H.Lundbeck A/S | Amino substituted aryloxybenzylpiperidine derivatives |
JP2006515618A (ja) * | 2003-01-14 | 2006-06-01 | ハー・ルンドベック・アクティーゼルスカブ | 置換アルキルアミドピペリジン類 |
WO2007075629A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
WO2008038692A1 (fr) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004241213B2 (en) * | 2003-05-21 | 2009-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminoquinoline derivative |
JPWO2005016928A1 (ja) * | 2003-08-15 | 2006-10-12 | 萬有製薬株式会社 | イミダゾピリジン誘導体 |
US7732456B2 (en) * | 2004-03-05 | 2010-06-08 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
JPWO2005108399A1 (ja) * | 2004-05-10 | 2008-03-21 | 萬有製薬株式会社 | イミダゾピリジン化合物 |
CA2582327A1 (en) * | 2004-10-01 | 2006-04-13 | Takao Suzuki | 2-arylcarboxamide-nitrogeneous heterocycle compound |
WO2007024004A1 (ja) * | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
WO2007029847A1 (ja) * | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
-
2008
- 2008-09-26 WO PCT/JP2008/067406 patent/WO2009041567A1/ja active Application Filing
- 2008-09-26 US US12/676,938 patent/US20100324049A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004536104A (ja) * | 2001-07-05 | 2004-12-02 | シナプティック・ファーマスーティカル・コーポレーション | Mch選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体 |
JP2006515618A (ja) * | 2003-01-14 | 2006-06-01 | ハー・ルンドベック・アクティーゼルスカブ | 置換アルキルアミドピペリジン類 |
WO2004069798A1 (ja) * | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
WO2006041635A2 (en) * | 2004-10-08 | 2006-04-20 | H. Lundbeck A/S | Arylthiobenzylpiperidine derivatives |
WO2006041636A2 (en) * | 2004-10-08 | 2006-04-20 | H.Lundbeck A/S | Amino substituted aryloxybenzylpiperidine derivatives |
WO2007075629A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
WO2008038692A1 (fr) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
WO2008047544A1 (fr) * | 2006-09-28 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Dérivé diarylcétimine |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11071729B2 (en) | 2007-09-14 | 2021-07-27 | Addex Pharmaceuticals S.A. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US9737533B2 (en) | 2009-05-12 | 2017-08-22 | Janssen Pharmaceuticals. Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
JP2012526737A (ja) * | 2009-05-12 | 2012-11-01 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
US10071095B2 (en) | 2009-05-12 | 2018-09-11 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders |
WO2010147234A1 (en) * | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
US8765771B2 (en) | 2010-06-25 | 2014-07-01 | Kowa Co., Ltd. | Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same |
JP5889788B2 (ja) * | 2010-06-25 | 2016-03-22 | 興和株式会社 | 新規な縮合ピリジン又は縮合ピリミジン誘導体及びこれを含有する医薬 |
WO2011162368A1 (ja) * | 2010-06-25 | 2011-12-29 | 興和株式会社 | 新規な縮合ピリジン又は縮合ピリミジン誘導体及びこれを含有する医薬 |
US10106542B2 (en) | 2013-06-04 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US10584129B2 (en) | 2013-06-04 | 2020-03-10 | Janssen Pharmaceuticals Nv | Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors |
US9708315B2 (en) | 2013-09-06 | 2017-07-18 | Janssen Pharmaceutica Nv | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors |
US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11103506B2 (en) | 2014-01-21 | 2021-08-31 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
US11369606B2 (en) | 2014-01-21 | 2022-06-28 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
JP2021528488A (ja) * | 2018-06-07 | 2021-10-21 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
US20100324049A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009041567A1 (ja) | メラニン凝集ホルモン受容体拮抗作用を有するジアリールケチミン誘導体 | |
TN2014000042A1 (en) | Cyclopropaneamine compound | |
WO2008005368A3 (en) | Piperazines as p2x7 antagonists | |
TNSN08407A1 (en) | Organic compounds | |
AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
JO3116B1 (ar) | مشتق بيرازولوكينولين كمثبطات ل pde9 | |
MX2009008541A (es) | Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c. | |
WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
TW200606152A (en) | Piperidine compound and process for preparing the same | |
MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
MX2009012125A (es) | Compuestos terapeuticos. | |
MX2009009355A (es) | Compuesto de bencimidazol y uso farmaceutico del mismo. | |
NZ603465A (en) | Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient | |
WO2008114812A1 (ja) | Jak阻害剤 | |
WO2012103071A3 (en) | Compounds and compositions | |
WO2010116140A8 (en) | New process for preparing hydroxylamines and medicaments | |
DK2868660T3 (da) | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse | |
TW200643019A (en) | Optically active tetrahydronaphthalene derivative | |
MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
WO2008141097A9 (en) | Stereoisomers propofol therapeutic compounds | |
NZ595113A (en) | Rosuvastatin and atorvastatin derivatives | |
TN2012000093A1 (en) | Therapeutic agent for anxiety disorders | |
EP2604261A3 (en) | SCCA-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient | |
TW200740782A (en) | Thiomorpholine compound and process for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08834051 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12676938 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08834051 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |